Top Page
Vita Life Sciences Limited
(Sydney:VLS)
Vita Life Sciences Limited (VLS) vs. iShares MSCI Australia ETF (EWA)
Vita Life Sciences Limited Business Overview & Revenue Model
Vita Life Sciences Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 85.60M | 79.50M | 74.16M | 66.89M | 57.10M | 46.48M |
| Gross Profit | 51.65M | 47.24M | 42.60M | 39.74M | 34.81M | 29.27M |
| EBITDA | 12.83M | 13.46M | 13.10M | 11.37M | 11.71M | 8.88M |
| Net Income | 9.33M | 8.78M | 9.08M | 7.08M | 8.29M | 6.09M |
Balance Sheet | ||||||
| Total Assets | 74.64M | 71.89M | 59.81M | 51.80M | 45.27M | 39.10M |
| Cash, Cash Equivalents and Short-Term Investments | 29.40M | 28.60M | 24.63M | 15.69M | 15.89M | 14.48M |
| Total Debt | 2.25M | 517.00K | 387.00K | 601.00K | 373.00K | 2.07M |
| Total Liabilities | 22.03M | 19.61M | 16.48M | 15.30M | 14.85M | 14.66M |
| Stockholders Equity | 52.71M | 52.35M | 43.40M | 36.57M | 30.75M | 24.72M |
Cash Flow | ||||||
| Free Cash Flow | 9.17M | 5.96M | 12.32M | 7.54M | 5.73M | 7.46M |
| Operating Cash Flow | 10.09M | 6.16M | 12.98M | 7.68M | 5.89M | 7.54M |
| Investing Cash Flow | -920.00K | -198.00K | -660.00K | -139.00K | -155.00K | -89.00K |
| Financing Cash Flow | -8.56M | -2.99M | -2.88M | -3.10M | -4.39M | -3.03M |
Vita Life Sciences Limited Technical Analysis
Vita Life Sciences Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | AU$146.38M | 16.19 | 18.35% | 4.33% | 8.46% | -1.95% | |
59 Neutral | AU$39.10M | 10.93 | 7.64% | 3.28% | 0.13% | -12.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$62.53M | 545.00 | 0.19% | ― | 17.82% | ― | |
37 Underperform | AU$20.97M | -2.68 | -35.58% | ― | 45.30% | -24.18% |
Vita Life Sciences Limited Corporate Events
Vita Life Sciences Limited has cancelled 18,584 ordinary fully paid shares on 19 December 2025 as part of an on-market share buy-back program, according to its latest capital notification. The reduction in issued capital forms part of the company’s ongoing capital management strategy and marginally increases the ownership percentage of remaining shareholders, signalling continued efforts to optimise its balance sheet and potentially enhance shareholder value.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences has issued its FY2025 guidance, projecting significant sales growth to $91m-$92m, up from $79.5m in FY2024, and a pre-tax profit increase to $13.2m-$13.7m. The growth is driven by robust performance in Malaysia and Singapore, with anticipated 30% revenue growth, and steady contributions from the Australian market. However, export sales to China are expected to fall short of initial expectations due to trade partner transitions. The company is committed to investing in brand development and market positioning to support long-term growth, focusing on core markets and exploring new opportunities in Vietnam and China.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update on its ongoing share buy-back program. The company reported that it bought back 18,584 ordinary fully paid securities on the previous day, adding to a total of 541,740 securities repurchased prior to that day. This buy-back initiative is part of Vita Life Sciences’ strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited announced the cessation of 3,062 ordinary fully paid securities due to an on-market buy-back, effective December 10, 2025. This move could potentially impact the company’s capital structure and market perception, as buy-backs are often seen as a signal of management’s confidence in the company’s future prospects.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited announced the cessation of 104,392 ordinary fully paid securities as part of an on-market buy-back, effective November 24, 2025. This move is likely to impact the company’s capital structure and could influence its market positioning by potentially increasing shareholder value through a reduction in outstanding shares.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, reporting the purchase of 31,265 ordinary fully paid securities on the previous day, adding to a total of 507,413 securities bought back to date. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach to managing its financial resources.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 29,959 ordinary fully paid securities bought back on the previous day, adding to the cumulative total of 477,454 securities repurchased before that day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced a daily update on their ongoing on-market buy-back of ordinary fully paid securities. As of November 6, 2025, the company has bought back a total of 434,286 securities, with an additional 4,954 securities purchased on the previous day. This buy-back strategy indicates the company’s efforts to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited announced the cessation of 226,873 of its ordinary fully paid securities due to an on-market buy-back, effective November 5, 2025. This move is part of the company’s capital management strategy, potentially impacting its market positioning by reducing the number of shares in circulation, which could influence shareholder value and market perception.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update regarding their ongoing on-market buy-back of ordinary fully paid securities. As of October 31, 2025, the company has repurchased a total of 432,689 securities, with an additional 1,597 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update regarding its ongoing share buy-back program. As of October 30, 2025, the company has bought back a total of 416,311 securities, with an additional 16,378 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program, detailing the acquisition of 8,898 ordinary fully paid securities on the previous day, bringing the total number of securities bought back to 407,413. This buy-back initiative reflects the company’s strategic efforts to optimize its capital structure and potentially enhance shareholder value, signaling confidence in its financial health and future prospects.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program, reporting the acquisition of 20,418 ordinary fully paid securities on the previous day. This buy-back initiative, which began on May 22, 2025, is part of the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, with a total of 372,413 securities bought back before the previous day and an additional 4,582 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially increase shareholder value.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update on its ongoing share buy-back program. The company reported the buy-back of 68,356 ordinary fully paid securities on the previous day, adding to a total of 289,032 securities bought back prior. This move is part of their strategy to manage capital efficiently, potentially improving shareholder value and market positioning.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update regarding its ongoing on-market buy-back program. As of October 17, 2025, the company has repurchased a total of 287,413 ordinary fully paid shares, including 23,000 shares bought back on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, with a total of 8,300 ordinary fully paid securities bought back on the previous day, adding to the cumulative total of 256,113 securities repurchased. This buy-back initiative is part of the company’s strategy to optimize its capital structure, potentially enhancing shareholder value and signaling confidence in its financial health.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update on its ongoing on-market buy-back program, with a total of 252,092 securities bought back prior to the previous day and an additional 4,021 securities acquired on the previous day. This buy-back initiative reflects the company’s strategy to enhance shareholder value and optimize its capital structure, potentially signaling confidence in its financial health and future performance.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.
Vita Life Sciences Limited has announced an update on its ongoing share buy-back program, with a total of 12,824 ordinary fully paid securities bought back on the previous day. This move is part of a strategic effort to consolidate its share capital, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
The most recent analyst rating on (AU:VLS) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Vita Life Sciences Limited stock, see the AU:VLS Stock Forecast page.